Dendritic cell-based immunotherapy (DCVAC/OvCa) withchemotherapy in patients with platinum-sensitive, relapsed,epithelial ovarian carcinoma: Survival analysis of a phase II,open-label, randomized, multicenter trial (study SOV02)

Bibliographic details

Authors

D. Cibula, L. Rob, P. Mallmann, P. Knapp, J. Bartůňková, R. Spíšek, H. I. Hassan, Ladislav Pecen, J. Klat, J. Chovanec

Publication year

2019

Publication type

Abstrakt

Periodical

Gynecologic Oncology

Bibliographic citation

CIBULA, D., ROB, L., MALLMANN, P., KNAPP, P., BARTŮŇKOVÁ, J., SPÍŠEK, R., HASSAN, H. I., PECEN, Ladislav, KLAT, J., CHOVANEC, J. Dendritic cell-based immunotherapy (DCVAC/OvCa) withchemotherapy in patients with platinum-sensitive, relapsed,epithelial ovarian carcinoma: Survival analysis of a phase II,open-label, randomized, multicenter trial (study SOV02). Gynecologic Oncology. 2019, 154(suppl. 1), 18-18. ISSN 0090-8258. E-ISSN 1095-6859
Dostupné z: doi:10.1016/j.ygyno.2019.04.046

DOI

10.1016/j.ygyno.2019.04.046

ID

506303